Venom: The Last Dance Underperforms at the Box Office
Venom: The Last Dance claimed the top spot at the U.S. box office with earnings of $51 million, but this figure fell short of expectations and marked the most disappointing opening weekend for the Venom trilogy, a Spider-Man spin-off.
Financial Expectations and Reception
According to a report from Variety, the third installment of the Venom series was anticipated to bring in $65 million in domestic ticket sales. This is particularly concerning given its production costs of $120 million, not including marketing expenses. On a global scale, the film grossed $124 million, bringing its total earnings to $175 million. Compared to its predecessors, the domestic earnings were significantly lower. The original Venom, with Tom Hardy in the lead as the anti-hero, generated $80 million domestically, while its sequel, Venom: Let There Be Carnage, achieved $90 million.
Critical Reception
The third film, which may conclude the series, also struggled in terms of critical acclaim, receiving a mere 4/10 rating in one review. Critics described the film as lacking, pointing out that its mundane plot and poor action sequences detracted from the otherwise strong dynamic between Eddie Brock and his symbiote companion.
Comparisons with Other Superhero Films
This film is not the only superhero sequel to stumble recently. Joker: Folie à Deux premiered earlier in October and faced similarly underwhelming financial and critical reception. Experts criticized its $37.8 million domestic earnings, and it received a slightly better review score of 5/10. Despite efforts by stars Joaquin Phoenix and Lady Gaga, along with an initial setup in Arkham Asylum, the film was found to fall short in its ambitions as a movie musical and a sequel, offering little new material or commentary compared to its predecessor.